VEGFA and lung cancer: The lower angiogenic potential and higher maturation fraction in BM from melanoma than in those from lung cancer may explain why the VEGF-A inhibitor, bevacizumab, blocks angiogenesis and results in the dormancy of the former, but not of the latter [36].